Crystal Structure of the Complex between the Fab′ Fragment of the Cross-Neutralizing Anti-HIV-1 Antibody 2F5 and the Fab Fragment of Its Anti-idiotypic Antibody 3H6

Journal of Molecular Biology

Volumn 382, Issue 4, 2008, Pages 910-919

  Bryson, Steve ^a,b   Julien, Jean Philippe ^a   Isenman, David E ^a   Kunert, Renate ^c   Katinger, Hermann ^c,d   Pai, Emil F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^d POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH   (Austria)

Author keywords

anti idiotypic; antibody; crystal structure; gp41; HIV 1

Indexed keywords

2F5 ANTIBODY; 3H6 ANTIBODY; EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 51449111685     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.07.057     Document Type: Article

References (47)

1. UNAIDS. (2006). Overview of the Global AIDS Epidemic. 2006 Report on the global AIDS epidemic.
2. Wilks D., and Dalgleish A.G. Anti-idiotypic therapeutic strategies in HIV infection. Mol. Cell. Biol. Hum. Dis. Ser. 1 (1992) 283-308
3. Center R.J., Leapman R.D., Lebowitz J., Arthur L.O., Earl P.L., and Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J. Virol. 76 (2002) 7863-7867
4. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384 (1996) 184-187
5. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273
6. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004) 233-236
7. Ho J., Uger R.A., Zwick M.B., Luscher M.A., Barber B.H., and MacDonald K.S. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 23 (2005) 1559-1573
8. Luo M., Yuan F., Liu Y., Jiang S., Song X., Jiang P., et al. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment. Vaccine 24 (2006) 435-442
9. Zhang H., Huang Y., Fayad R., Spear G.T., and Qiao L. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine papillomavirus-HIV-1 gp41 chimeric virus-like particles. J. Virol. 78 (2004) 8342-8348
10. Joyce J.G., Hurni W.M., Bogusky M.J., Garsky V.M., Liang X., Citron M.P., et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J. Biol. Chem. 277 (2002) 45811-45820
11. Xiao Y., Zhao Y., Lu Y., and Chen Y.H. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody. Immunol. Invest. 29 (2000) 41-50
12. Coeffier E., Clement J.M., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19 (2000) 684-693
13. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., Katinger H., and Rüker F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77 (1996) 2001-2008
14. Jerne N.K. Towards a network theory of the immune system. Ann. Immunol. 125C (1974) 373-389
15. Jerne N.K., Roland J., and Cazenave P.A. Recurrent idiotopes and internal images. EMBO J. 1 (1982) 243-250
16. Bona C.A., and Kohler H. Anti-idiotypic antibodies and internal images in monoclonal and anti-idiotypic antibodies. In: Venter J.C., Fraser C.M., and Linstrom J. (Eds). Monoclonal and Anti-idiotypic Antibodies: Probes for Receptor Structure and Function (1984), A. R. Liss, New York 141-149
17. Dalgleish A.G., and Kennedy R.C. Anti-idiotypic antibodies as immunogens: idiotype-based vaccines. Vaccine 6 (1988) 215-220
18. Zhou E.M., Lohman K.L., and Kennedy R.C. Administration of noninternal image monoclonal anti-idiotypic antibodies induces idiotype-restricted responses specific for human immunodeficiency virus envelope glycoprotein epitopes. Virology 174 (1990) 9-17
19. Chanh T.C., Dreesman G.R., and Kennedy R.C. Monoclonal anti-idiotypic antibody mimics the CD4 receptor and binds human immunodeficiency virus. Proc. Natl Acad. Sci. USA 84 (1987) 3891-3895
20. Chang C.C., Hernandez-Guzman F.G., Luo W., Wang X., Ferrone S., and Ghosh D. Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J. Biol. Chem. 280 (2005) 41546-41552
21. Mosolits S., Campbell F., Litvinov S.V., Fagerberg J., Crowe J.S., Mellstedt H., and Ellis J.H. Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines. Int. J. Cancer 112 (2004) 669-677
22. Stein K.E., and Soderstrom T. Neonatal administration of idiotype or anti-idiotype primes for protection against Escherichia coli K13 infection in mice. J. Exp. Med. 160 (1984) 1001-1011
23. Garcia K.C., Ronco P.M., Verroust P.J., Brünger A.T., and Amzel L.M. Three-dimensional structure of an angiotensin II-Fab complex at 3 Å: hormone recognition by an anti-idiotypic antibody. Science 257 (1992) 502-507
24. Kunert R.E., Weik R., Ferko B., Stiegler G., and Katinger H. Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. AIDS 16 (2002) 667-668
25. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 (1993) 6642-6647
26. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10 (1994) 1651-1658
27. Root M., and Steger H.K. HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. Des. 10 (2004) 1805-1825
28. Gach J.S., Quendler H., Strobach S., Katinger H., and Kunert R. Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5. Mol. Immunol. 45 (2008) 1027-1034
29. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., and Foeller C. Sequences of proteins of immunological interest (1991), Department of Health and Human Services, Washington, DC
30. Gach J.S., Maurer M., Hahn R., Gasser B., Mattanovich D., Katinger H., and Kunert R. High level expression of a promising anti-idiotypic antibody fragment vaccine against HIV-1 in Pichia pastoris. J. Biotechnol. 128 (2007) 735-746
31. Gach J.S., Quendler H., Weik R., Katinger H., and Kunert R. Partial humanization and characterization of an anti-idiotypic antibody against monoclonal antibody 2F5, a potential HIV vaccine?. AIDS Res. Hum. Retroviruses 23 (2007) 1405-1415
32. Matthews B.W. Solvent content of protein crystals. J. Mol. Biol. 33 (1968) 491-497
33. Tsodikov O.V., Record Jr. M.T., and Sergeev Y.V. A novel computer program for fast exact calculation of accessible and molecular surface areas and average surface curvature. J. Comput. Chem. 23 (2002) 600-609
34. Martin A.C.R. Accessing the Kabat antibody sequence database by computer. Proteins: Struct. Funct. Genet. 25 (1996) 130-133
35. Zwick M.B., Komori H.K., Stanfield R.L., Church S., Wang M., Parren P.W., et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78 (2004) 3155-3161
36. Pai, E. F., Klein, M. H., Chong, P. & Pedyczak, A. (2000). Fab′-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5. World Intellectual Property Organization patent WO-00/61618.
37. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., and Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 (2004) 10724-10737
38. Julien, J.-P., Bryson, S., Nieva, J. L. & Pai, E. F. (2008). Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, 2F5 CDR H3 loop mobility and anion-binding site. J. Mol. Biol. Submitted for publication.
39. Tian Y., Ramesh C.V., Ma X., Naqvi S., Patel T., Cenizal T., et al. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. J. Pept. Res. 59 (2002) 264-276
40. Menendez A., Chow K.C., Pan O.C., and Scott J.K. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J. Mol. Biol. 338 (2004) 311-327
41. Bryson S., Cunningham A., Ho J., Hynes R.C., Isenman D., Barber B., et al. Cross-neutralizing monoclonal anti-HIV-1 antibody 2F5: preparation and crystallographic analysis of free and epitope-complexed forms of Fab′. Protein Pept. Lett. 8 (2001) 413-418
42. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
43. Otwinowski Z., and Minor M. Processing of X-ray diffraction data collected in oscillation mode. In: Carter Jr. C.W., and Sweet R.M. (Eds). Methods in Enzymology, Vol. 276: Macromolecular Crystallography, Part A (1997), Academic Press, New York 307-326
44. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26 (1993) 795-800
45. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography and NMR system (CNS): a new software system for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 54 (1998) 905-921
46. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 (2004) 2126-2132
47. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, Palo Alto, CA